"Optimal Clinical Trials is a private research site dedicated to conducting world-class outpatient phase Ib to 3 clinical medical trials for global biopharma and CROs."

During the past decade, Optimal Clinical Trials conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 8 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 5 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Optimal Clinical Trials" #1 sponsor was "Pfizer" with 4 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Akesobio Australia Pty Ltd" with 1 trials sponsored, "Axial Therapeutics, Inc." with 1 trials sponsored and "Becton, Dickinson and Company" with 1 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Optimal Clinical Trials" #1 collaborator was "Syneos Health" with 2 trials as a collaborator, "Celtaxsys Aus Pty Limited" with 1 trials as a collaborator, "Clinical Network Services (CNS) Pty Ltd" with 1 trials as a collaborator, "Department of Health and Human Services" with 1 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Optimal Clinical Trials" are "Atopic Dermatitis" (2 trials), "COVID-19" (2 trials), "Cardiovascular Disease" (2 trials), "Influenza" (2 trials) and "SARS-CoV-2 Infection" (2 trials). Many other conditions were trialed in "Optimal Clinical Trials" in a lesser frequency.

Most popular intervention types in "Optimal Clinical Trials" are "Drug" (18 trials), "Biological" (7 trials), "Diagnostic Test" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "BI 456906" (2 trials), "bococizumab (PF-04950615)" (2 trials), "40 mg Laninamivir Octanoate" (1 trials) and "80 mg Laninamivir Octanoate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Optimal Clinical Trials" are 23 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Optimal Clinical Trials". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Optimal Clinical Trials, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Optimal Clinical Trials, 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".